White Paper

Gene Therapy Applied To Mitochondrial Disease: A Guide To Emerging Regulatory Pathways - Part 2

By Kaitlyn Rouillard, PhD, Regulatory Scientist, and Rachel Ward, PhD, Associate Director, Regulatory Affairs

Gene Therapy GettyImages-1164556175

Continuing from our discussion in "Gene Therapy Applied to Mitochondrial Disease: A Guide to Emerging Regulatory Pathways - Part 1," recent breakthroughs in gene therapy have ignited enthusiasm for its use in treating primary mitochondrial diseases (PMDs). Unlike current therapies that solely manage symptoms, gene therapy for PMDs offers the possibility of complete or partial remission, a revolutionary prospect for patients. This promising development aligns with the FDA's priority of delivering innovative and effective treatments to patients with rare diseases as swiftly as possible. Consequently, the FDA has established various incentives and mechanisms to encourage sponsors to develop drugs for rare diseases.

This second part delves into the strategies and FDA recommendations for implementing gene therapy development programs, specifically designed for PMDs.

access the White Paper!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Cell & Gene